Consumer goods giant Unilever signalled on Monday (January 17) it would pursue a deal for GlaxoSmithKline's consumer healthcare business, calling it a "strong strategic fit" after its £50 billion offer was refused.
GSK confirmed on Saturday that it had rejected three approaches from the Dove-soap maker, adding it intended to stick to its own plan to spin off the business as a separate company later this year.
"GSK Consumer Healthcare would be a strong strategic fit," Unilever said in a statement as it unveiled a strategy update in the wake of the weekend's takeover news.
Unilever said it was "committed to accelerating the company's growth and repositioning the portfolio into higher growth categories.
"As a result of the reporting of Unilever's interest in GSK Consumer Healthcare, we are today bringing forward a planned update, setting out the strategic direction that the company is pursuing," Unilever said.
Boots is planning to invest more than £3.5 million to accelerate its capacity to offer prescribing services in its stores across England.
The company is inviting 500 of its pharmacists to apply for a bursary which will cover the cost of pharmacist independent prescriber (PIP) courses starting this
September.
The value of the bursary is up to £7,000 per pharmacist, and it will enable time off work for those who need it to complete the training.
The move by Boots will support its current pharmacists to gain this qualification via courses accredited by the General Pharmaceutical Council (GPhC). From 2026,
all qualified pharmacists will be able to prescribe as part of new curricula for pharmacy degrees.
Under current GPhC guidelines and with an independent prescribing qualification, pharmacists can prescribe autonomously for any condition within their clinical
competence.
Marc Donovan, the chief pharmacist at Boots, said the ambition of the company was "to have a pharmacist prescriber available at every store".
An international specialty pharmaceutical group, Essential Pharma has announced the completion of two transactions with fellow UK-based Rosemont Pharmaceuticals.
The company completed the divestment of its oral liquid portfolio to Rosemont, and acquired a series of attractive, niche products with "geographic expansion potential."
Commenting on the announcement, Essential Pharma chief executive Steen Vangsgaard said: "The Rosemont products bring additional niche products into our portfolio with international expansion potential.
"The divestiture of our UK oral liquid products streamlines our portfolio, allowing us to focus and accelerate our strategic growth ambition of building a leading international specialty pharma platform."
Under the divestment deal, Rosemont Pharmaceuticals will acquire the product portfolio of licences, registrations and trademarks, as well as related commercial rights, to a number of oral generic products which are used to treat a range of conditions in various therapeutic areas.
The National Pharmacy Association (NPA) has commissioned Professor David Taylor of University College London to investigate the implications of all-time high
inflation rates on community pharmacies in the UK.
Professor Taylor's will assess rates of inflation affecting community pharmacy across the UK, using public data sources whilst examining inflated costs in the
context of the current five year contractual framework in England (2019-2024).
He would review the EY (Ernst & Young) report into pharmacy funding, to identify whether current inflationary pressures could change any of the findings and
consider the policy implications and impacts of inflationary pressures, including pharmacy's ability to prepare for a more clinically focused future and maintain
current core services.
NPA chief executive Mark Lyonette said: "Inflationary pressures are eating into the limited funds provided by the NHS for pharmacy services. We believe the real
level of inflation for pharmacy businesses could be higher than the CPI inflation rate, which itself is at a 40 year high. Staff and locum costs in the sector as
well as medicines costs have risen dramatically.
Monkeypox appears to be spreading from person to person in England, the UK Health Security Agency (UKHSA) said on Wednesday (June 1).
The usually mild viral disease, which is endemic in west and central Africa, is understood to spread through close contact. Until early May, cases rarely cropped
up outside Africa and were typically linked to travel to there.
"The current outbreak is the first time that the virus has been passed from person to person in England where travel links to an endemic country have not been
identified," the agency said.
According to the UKHSA, the majority of cases in the United Kingdom - 132 - are in London, while 111 cases are known to be in gay, bisexual, or other men who
have sex with men. Only two cases are in women.
Recent foreign travel to a number of different countries in Europe within 21 days of symptom onset has been reported by 34 confirmed cases, or about 18 per cent
of the 190 cases of the disease that have been confirmed by the United Kingdom as of May 31.
After a series of internal pay negotiations and conciliation meetings, Boots has made a revised pay offer to its pharmacists.
With the new development, the Pharmacists' Defence Association (PDA) has urged its members at Boots to "urgently respond to the Boots pay negotiations update survey on the current pay offer."
It encouraged the members to complete the short survey sent to them via email.
Last week, the PDA Reps Network in Boots hosted a series of virtual meetings for members that work at the company.
As the element of the negotiations with Advisory, Conciliation and Arbitration Service (ACAS) are ongoing, PDA could not provide more details about these meetings.
The Pharmacists' Defence Association (PDA) has launched a brutal attack on some large pharmacy chains for full or part-day closures of some of their shops
throughout the UK.
It published an Open Letter on Tuesday (July 19) demanding urgent action "to protect patients by ensuring that essential community pharmacy services are provided
safely and consistently".
PDA chair Mark Koizol, who wrote the letter, went on to allege that many of those closure were "being orchestrated".
He wrote that the "pharmacist shortage" narrative cited as a reason for these closures was "very different" from "the reality experienced by our members", including
both employed and locum pharmacists.
"We have evidence to show that these closures are being announced up to four weeks in advance," Koizol claimed.
He gave examples of how a large company attempted to reduce the pre-agreed rate of locums and where this was not accepted, the shift was cancelled, resulting in the
pharmacy being closed for part or full day.
Indian authorities have cancelled or suspended licences of some domestic drug companies as part of action taken against 76 pharmaceutical firms this month for
selling adulterated or fake products, a government source said on Thursday.
India is known as the 'pharmacy of the world' and its pharmaceuticals exports have more than doubled over the past decade to $24.5 billion in 2021-22.
But that image has been dented by the death of at least 70 children in Gambia and 19 children in Uzbekistan in Uzbekistan last year linked to drugs made by
India-based pharmaceutical companies.
Health Minister Mansukh Mandaviya confirmed a crackdown but did not give details of companies against which action had been taken.
"There are more than 10,500 pharma companies in the country. Companies who make spurious medicine will not be spared," Mandaviya told reporters at an event.
Licences of some Indian drug companies have been cancelled, some were suspended while others have been put on notice during the past 15 days, the source, who had
direct knowledge of the matter, told Reuters news agency.
Community Pharmacies are set to significantly upgrade their digital security as the mandatory rollout of NHSmail Multi-Factor Authentication (MFA) begins
this month (August 1, 2024).
In an announcement by the Community Pharmacy England (CPE), pharmacies are urged to make the updates following a period of optional MFA implementations that began
in late 2023.
According to the new requirements, the mandatory update is crucial for protecting patient privacy and the integrity of their health records.
By adding an extra layer of security beyond the standard email address and password, MFA helps safeguard against unauthorised access.
This is especially vital in light of increasing cyber threats targeting healthcare systems.
Cyberattacks, including ransomware, can compromise patient records and disrupt care delivery, making robust security measures essential.
The introduction of MFA aims to curb these risks.
According to cybersecurity research, MFA can prevent up to 80 per cent data breaches and block over 99.9 per cent of compromised accounts.
Wockhardt UK managing director Ravindra Limaye has been chosen for honorary British awards given to foreign nationals.
Limaye gets the Order of the British Empire (OBE) honour for his contribution to health, particularly during the Covid-19 pandemic.
The honours were announced on Thursday (13).
Limaye has been the chief executive of the UK arm of the Mumbai-based pharma and biotech company Wockhardt since 2019.
He previously worked for another Indian pharma company Biocon, overseeing its global commercial operations. He led the company's entry into global biosimilar
markets and spearheaded its operations in the US.
Polio has been detected in sewage samples in London, the first sign since the 1980s that the virus could be spreading in the UK, but no cases have been found,
authorities said.
The risk of infection from the disease, which causes paralysis in children in under one per cent of cases, was also low because of high vaccination rates, the UK
Health Security Agency (UKHSA) said.
The agency nevertheless encouraged parents to make sure their children were vaccinated after the discovery of the virus during routine wastewater surveillance -
particularly those who may have missed shots during the Covid-19 pandemic.
Nationwide vaccination levels are above the 90 per cent needed to prevent outbreaks, but London's coverage rates among the under-twos has dipped below that in recent
years.
NHS England will begin contacting parents of children under five who are not immunised.
Polio, spread mainly through contamination by faecal matter, used to kill and paralyse thousands of children annually worldwide. There is no cure, but vaccination
brought the world close to ending the wild, or naturally occurring, form of the disease.
The UK Health Security Agency (UKHSA) has said that monkeypox is to be listed as a notifiable disease in law from Wednesday (June 8).
The new legislation means all doctors in England are required to notify their local council or local Health Protection Team (HPT) if they suspect a patient has monkeypox. Laboratories must also notify the UKHSA if the monkeypox virus is identified in a laboratory sample.
Wendi Shepherd, monkeypox incident director at UKHSA, said: "Rapid diagnosis and reporting is the key to interrupting transmission and containing any further spread of monkeypox. This new legislation will support us and our health partners to swiftly identify, treat and control the disease.
"It also supports us with the swift collection and analysis of data which enables us to detect possible outbreaks of the disease and trace close contacts rapidly, whilst offering vaccinations where appropriate to limit onward transmission."
Department of Health and Social Care (DHSC) has updated the final price concessions for June 2023, following a discussion by Community Pharmacy England
regarding medicine pricing issues reported by pharmacy owners (its members).
A price concession only applies for the month it is granted; any prices agreed for concessions requested late in the month will roll over into the following month.
Community Pharmacy England encouraged pharmacies to report any problems obtaining a Part VIII product at or below the stated Drug Tariff price, using the online
feedback form on the Community Pharmacy England website along with full details of the supplier and price paid for any products sourced above the Drug Tariff price.
The association will investigate the extent of the problem and, if appropriate, discuss the issue with DHSC.
The Pharmacists' Defence Association has asked Boots UK to waive any restrictive clause that prevents pharmacists working with the multiple from working for other pharmacy employers, even after leaving the company.
However, the firm is yet to respond to the formal request, PDA said in an update.
This request follows demand from the association members shortly after the company announced it's plans to cut opening hours.
On workforce shortages, the PDA stated if there was a genuine shortage, then preventing pharmacists from working for other pharmacy employers to make up for the lost hours would be counterproductive and it would further exacerbate any "shortage".
Salrook Healthcare, a family-run pharmacies in Chester has sold its two well-established community pharmacies named Westminster Park Pharmacy on Castle Croft
Road and Owen's Chemist on Chester Street. Together, they dispense circa 13,000 items per month.
The business has been owned by the Persaud family since 2014 and was recently brought to the market as a retirement sale. Following a confidential process with
Christie & Co, it has been purchased by Aqib Sheikh, an existing operator with a pharmacy in Walsall, West Midlands. Aqib plans to enhance the business's service
offering and grow his portfolio in the region.
Chloe Yadav (nee Persaud), previous owner of Salrook Healthcare Limited, comments, "As a family, we are delighted to have completed the sale of the business to Aqib.
Whilst we will miss our team who have become like family, it is good to know that the two sites have been acquired by a forward- thinking Pharmacist who will enhance
the offering to the benefit of the patients and the community which they serve. My family and I wish Aqib and the whole team the very best of luck with the future."
Aqib Sheikh, new owner of Salrook Healthcare Limited, comments, "I am delighted to have inherited such a well-run and profitable pair of pharmacy businesses in the
charming city of Chester. I'd like to wish John Persaud the very best with his retirement and look forward to building on the work of the Persaud family."
The Community Pharmacy England Committee has adopted a new approach to engagement with sector by inviting all pharmacy owners to share their views on
pharmacy's finances, pressures and capacity ahead of its meeting in July.
It has sought views of pharmacists via short poll by Sunday (2 July) and will have a discussion on the poll results at the meeting before reporting back to the
sector afterwards.
The key focus for July Committee Meeting will be to make most of £645m for the community pharmacy sector, and also on the ongoing work to make the wider case for
more investment in the sector.
This new way of working follows association's rebrand on 30th May which signalled the start of its new approach to engagement to help them to build stronger
relationships with pharmacy owners.
The association hopes this new approach will help them better engage with members and listen to pharmacy's views better.
The National Pharmacy Association (NPA) Board has elected 14 Board members on Friday (30 March) that will govern the association for next two years.
Four new Board members have been elected while five previous members left the Board after serving their terms. The period April 2023 to March 2025 will see the
completion of the transition to the new Board structure.
The Board will meet again on Monday (24 April) to elect the Chair and other appointments.
Gareth Jones, Returning Officer for the NPA Board elections, said: "The NPA has undertaken a process of significant modernisation of organisational governance over
the past years. Key elements of this process include adopting modern new Articles of Association, reforming the structure of the Board and introducing term limits.
The process of electing the Board has also been changed so that half of the Board will be up for election every two years - which supports continuity and reduces the
risk of a loss of organisational memory."
"Recognising that the Board would already be losing a lot of organisational memory in 2023 with five members of Board standing down, the Board determined that three
individuals should be co-opted onto the new Board as the process of transformation continues. In March 2025, anyone that has served 12 years or more will be required
to stand down."
The Medicines and Healthcare products Regulatory Agency (MHRA) on Tuesday authorised a Covid-19 vaccine for infants as young as six months, opening the door
for vaccinating the country's youngest children once the UK's Joint Committee on Vaccination and Immunisation (JCVI) agrees.
The regulator authorised the vaccine - made by Pfizer and BioNTech - for children aged six months to four years old, after it was deemed safe and effective based on
an ongoing clinical trial involving 4,526 participants.
Whether the vaccine is eventually deployed in this age group depends on a recommendation from the JCVI, which advises UK health departments on which shots should be
used as part of the national vaccination programme.
The vaccine is tailored for use in this age group - it is a lower dose version than the one used in children aged five to 11 years. It is given as three injections
in the upper arm, with the first two doses given three weeks apart, followed by a third dose administered at least two months after the second dose.
Kent based N.B. Pharmacy has been sold to first-time buyers, Venkat and Preeti Adama, from Essex for an undisclosed price.
N.B. Pharmacy is a standard hours community pharmacy that dispenses an average of 6,393 items per month.
The business has been owned by Nirmal Bajaria for 39 years and was recently brought to market to allow him to pursue a well-earned retirement. Following a
confidential sales process with Christie & Co, it has been purchased by first-time buyers, Venkat and Preeti Adama, from Essex.
Nirmal Bajaria, former owner of N.B. Pharmacy, comments, "Having run the pharmacy for around 39 years, it was a difficult decision to put the business up for sale.
I was very pleased with the high number of viewers and feel delighted that a young family bought my pharmacy."
Community Pharmacy England (CPE) has notified pharmacy teams that starting 1 August 2024, three Hormone Replacement Therapy (HRT) medicines will be
discontinued and will no longer be covered under the NHS HRT Prescription Prepayment Certificate (HRT PPC) scheme.
These are Bedol® 2mg tablets, Climanor® 5mg tablets and Clinorette® tablets.
Since Climanor® 5mg tablets have been discontinued, Medroxyprogesterone 5mg tablets will also be removed from the HRT PPC list, as this generic product is no
longer available as a licensed HRT medicine.
The CPE also noted that Provera® 5mg tablets, being an unlicensed HRT medicine, are not covered by the HRT PPC.
Pharmacy staff are advised to check the NHS Business Services Authority (NHSBSA) website for the most current list of HRT medicines covered by the HRT PPC.
The CPE has updated its HRT PPC medicines list to reflect these changes, which will also be updated in Part XVI of the August 2024 Drug Tariff.